Ignite Creation Date:
2025-12-25 @ 2:06 AM
Ignite Modification Date:
2025-12-27 @ 4:40 AM
Study NCT ID:
NCT01152060
Status:
UNKNOWN
Last Update Posted:
2010-06-29
First Post:
2010-06-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial
Sponsor:
Nanchang University
Organization:
Study Overview
Official Title:
an Open Parallel Clinical Trial in HBV-GN Patients
Status:
UNKNOWN
Status Verified Date:
2010-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Lamivudine treatment for HBV-DNA negative HBV-GN patients.
Detailed Description:
lamivudine and predinisone treatment for HBV-DNA negative HBV-GN patients.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: